Last reviewed · How we verify
NCT06188858
Optimal Incision Site Design for Lymphaticovenular Anastomosis in Extremity Lymphedema
trial in Lymphedema in 267 participants. Completed in 1 December 2023.
1 December 2023
Quick facts
| Lead sponsor | Taizhou Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 267 |
| Start date | 1 January 2020 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across China |
Conditions studied
- Lymphedema — all drugs for Lymphedema →
Sponsor
Taizhou Hospital
Who can join
Adults 18 to 80, any sex, with Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our aim was to identify optimal incision sites for LVA in extremity lymphedema that would result in the most effective drainage effect for reducing limb edema and enhancing patients' quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06188858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphedema
Currently open trials in the same condition.
- NCT07489248 — Multimodal Ultrasound for Differentiating Lymphedema and Lipedema · recruiting
- NCT07448467 — Investigation of the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema. · NA · recruiting
- NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
- NCT06866197 — CONNECT: A Multi-Cohort, Prospective Investigation of the Symani® Surgical System · NA · recruiting
Other Taizhou Hospital trials
Trials by the same sponsor.
- NCT06997614 — Enhancing Critical Thinking Competency and Nursing Quality in Critically Ill Patient Care · NA · completed
- NCT06902935 — Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four · not yet recruiting
- NCT06441344 — Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell · Phase 3 · not yet recruiting
- NCT07127809 — Mindfulness-Based Intervention Targeting Psychological Capital to Reduce Job Burnout Among Nurses · NA · completed
- NCT06319950 — High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06188858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taizhou Hospital
- Last refreshed: 3 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06188858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing